James W Smithy, Hannah L Kalvin, Fiona D Ehrich, Ronak Shah, Matthew Adamow, Vladislav Raber, Colleen A Maher, Jenna Kleman, Debra A G McIntyre, Alexander N Shoushtari, Allison Betof Warner, Margaret K Callahan, Parisa Momtaz, Omar Eton, Suresh Nair, Jedd D Wolchok, Paul B Chapman, Michael F Berger, Katherine S Panageas, Michael A Postow
PURPOSE: ADAPT-IT (NCT03122522) investigated adaptive ipilimumab discontinuation in melanoma based on early radiographic assessment. Initial findings indicated similar effectiveness compared to conventional nivolumab-ipilimumab (nivo-ipi). Exploratory biomarker analyses and final clinical results are now reported. PATIENTS AND METHODS: Patients with unresectable melanoma received two doses of nivo-ipi. Radiographic assessment at Week 6 informed continuation of ipilimumab before nivolumab maintenance...
May 20, 2024: Clinical Cancer Research